IDEXX Laboratories Company Profile (NASDAQ:IDXX)

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Veterinary Medical Equipment & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:IDXX
  • CUSIP: 45168D10
  • Web:
  • Market Cap: $13.75 billion
  • Outstanding Shares: 87,275,000
Average Prices:
  • 50 Day Moving Avg: $154.86
  • 200 Day Moving Avg: $159.27
  • 52 Week Range: $102.45 - $173.01
  • Trailing P/E Ratio: 54.18
  • Foreward P/E Ratio: 44.49
  • P/E Growth: 2.59
Sales & Book Value:
  • Annual Revenue: $1.86 billion
  • Price / Sales: 7.39
  • Book Value: ($0.99) per share
  • Price / Book: -159.09
  • EBIDTA: $467.99 million
  • Net Margins: 16.78%
  • Return on Assets: 21.35%
  • Debt-to-Equity Ratio: -6.98%
  • Current Ratio: 0.92%
  • Quick Ratio: 0.75%
  • Average Volume: 566,795 shs.
  • Beta: 0.49
  • Short Ratio: 4.18

Frequently Asked Questions for IDEXX Laboratories (NASDAQ:IDXX)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its board has approved a share buyback program on Sunday, June 4th 2017, which allows the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Tuesday, August, 1st. The company reported $0.95 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million for the quarter, compared to analyst estimates of $502.44 million. The firm's revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.74 earnings per share. View IDEXX Laboratories' Earnings History.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $3.12-3.22 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.07. The company issued revenue guidance of $1.945-1.965 billion, compared to the consensus revenue estimate of $1.94 billion.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?

6 brokerages have issued 12 month target prices for IDEXX Laboratories' stock. Their predictions range from $118.00 to $200.00. On average, they anticipate IDEXX Laboratories' stock price to reach $171.60 in the next year. View Analyst Ratings for IDEXX Laboratories.

What are analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "IDEXX continues to demonstrate solid growth globally with strong international expansion. Management’s innovation-based global strategy is leading to its CAG Diagnostics growth. Solid organic revenue growth buoys optimism. Moreover, the company recently expanded its cloud technology portfolio by adding rVetLink to it. IDEXX’s last reported first quarter was also impressive with earnings and revenues growing year over year. The raised 2017 EPS guidance is also encouraging. Notably,  over the last six months, the company has been trading above the broader Medical Instruments industry. On the other hand, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation also remains a concern." (7/19/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
  • Jay Mazelsky, Executive Vice President
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
  • William T. End, Lead Independent Director
  • Bruce L. Claflin, Independent Director
  • Stuart M. Essig Ph.D., Independent Director
  • Rebecca M. Henderson Ph.D., Independent Director
  • Daniel M. Junius, Independent Director

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.62%), BlackRock Inc. (8.14%), Bamco Inc. NY (5.42%), Fundsmith LLP (5.09%), State Street Corp (4.39%) and Blair William & Co. IL (2.04%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, JPMorgan Chase & Co., Fiera Capital Corp, Bamco Inc. NY, Neuberger Berman Group LLC, Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado and Prudential Financial Inc.. Company insiders that have sold IDEXX Laboratories stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Koch Industries Inc., Janus Henderson Group PLC, BlackRock Inc., Old Mutual Global Investors UK Ltd., Arrowstreet Capital Limited Partnership, Renaissance Technologies LLC, Goldman Sachs Group Inc. and Vanguard Group Inc.. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $157.50.

MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IDEXX Laboratories (NASDAQ:IDXX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $171.60 (8.95% upside)

Analysts' Ratings History for IDEXX Laboratories (NASDAQ:IDXX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/23/2017Bank of America CorporationUpgradeNeutral -> Buy$175.00LowView Rating Details
8/22/2017Canaccord GenuityReiterated RatingBuy$180.00LowView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$185.00LowView Rating Details
7/28/2017CL KingUpgradeNeutral -> Buy$200.00MediumView Rating Details
5/31/2017AegisInitiated CoverageSell$118.00LowView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 -> $75.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for IDEXX Laboratories (NASDAQ:IDXX)
Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Earnings History by Quarter for IDEXX Laboratories (NASDAQ IDXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017$0.85$0.95$502.44 million$508.90 millionViewListenView Earnings Details
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IDEXX Laboratories (NASDAQ:IDXX)
2017 EPS Consensus Estimate: $2.88
2018 EPS Consensus Estimate: $3.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.59$0.61$0.60
Q2 20173$0.82$0.88$0.85
Q3 20173$0.74$0.75$0.75
Q4 20173$0.67$0.72$0.69
Q1 20181$0.78$0.78$0.78
Q2 20181$1.10$1.10$1.10
Q3 20181$0.83$0.83$0.83
Q4 20181$0.82$0.82$0.82
(Data provided by Zacks Investment Research)


Dividend History for IDEXX Laboratories (NASDAQ:IDXX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IDEXX Laboratories (NASDAQ:IDXX)
Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 87.64%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/28/2017Jonathan W AyersChairmanSell13,000$150.79$1,960,270.00View SEC Filing  
8/23/2017Rebecca M HendersonDirectorSell5,156$153.29$790,363.24View SEC Filing  
8/22/2017Rebecca M HendersonDirectorSell2,578$152.86$394,073.08View SEC Filing  
8/16/2017Jonathan W AyersChairmanSell58,000$155.00$8,990,000.00View SEC Filing  
8/15/2017Jonathan W AyersCEOSell20,000$154.62$3,092,400.00View SEC Filing  
8/14/2017Jonathan W AyersCEOSell18,000$154.91$2,788,380.00View SEC Filing  
8/9/2017Jonathan W AyersChairmanSell17,000$154.54$2,627,180.00View SEC Filing  
8/8/2017Jonathan W. AyersChairmanSell18,000$155.22$2,793,960.00View SEC Filing  
8/3/2017Lawrence D KingsleyDirectorBuy2,000$151.76$303,520.00View SEC Filing  
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.00View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.00View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.00View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.00View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.00View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.36View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.00View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.48View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.16View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.00View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.00View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.32View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.88View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.00View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.88View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.00View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.08View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.10View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.00View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.00View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.00View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.24View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.00View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.00View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.00View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.00View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.00View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.80View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.52View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IDEXX Laboratories (NASDAQ:IDXX)
Latest Headlines for IDEXX Laboratories (NASDAQ:IDXX)
DateHeadline logoHere's Why Investors Should Buy Masimo (MASI) Right Now - Nasdaq - September 22 at 6:51 PM logoBD (BDX) Inks New Deal to Strengthen Foothold in STI Space - Nasdaq - September 22 at 1:50 PM logoHere's Why You Should Invest in IDEXX Laboratories (IDXX) Now - Nasdaq - September 22 at 1:50 PM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : September 22, 2017 - September 22 at 1:50 PM logoMasimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance - Nasdaq - September 19 at 7:50 PM logoVarian Medical (VAR) Releases FDA-Approved Eclipse 15.5 - Nasdaq - September 19 at 7:50 PM logoSurmodics Receives FDA's Approval for PTA Balloon Catheter - Nasdaq - September 19 at 7:50 PM logoBruker (BRKR) Strong on Product Launches Amid Currency Woes - Nasdaq - September 19 at 7:50 PM logoVarian Conducts Clinical Workshop, Strengthens Algeria Hold - Nasdaq - September 19 at 12:17 AM logoMcKesson to Gain From Distribution Business Amid Pricing Woes - Yahoo Finance - September 19 at 12:17 AM logo$493.63 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter - September 15 at 1:04 AM logoHere's Why Investors Should Buy Luminex (LMNX) Right Now - September 14 at 11:44 PM logoIDEXX Laboratories (IDXX) Presents At Bank Of America Merrill Lynch 2017 Global Real Estate Conference - Slideshow - September 14 at 11:44 PM logoIDEXX Laboratories, Inc. (IDXX) Given Average Recommendation of "Hold" by Brokerages - September 13 at 4:44 PM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : September 12, 2017 - September 13 at 2:10 AM featured highlights include Lululemon Athletica, Sanderson Farms, IDEXX Laboratories and NVR - September 13 at 2:10 AM logo5 Top-Ranked MedTech Growth Stocks for Solid Returns - Nasdaq - September 12 at 1:15 AM logo5 Top-Ranked MedTech Growth Stocks for Solid Returns - September 11 at 8:13 PM logoBuy These 4 Efficient Stocks for Healthy Returns - September 11 at 8:12 PM logoEcolab (ECL) Features in DJSI List for Third Consecutive Year - September 11 at 8:12 PM logoIDEXX Laboratories to Present at Bank of America Merrill Lynch Global Healthcare Conference - September 6 at 7:40 PM logoMazor Robotics Hits 52-Week High Through Medtronic Alliance - September 4 at 6:41 PM logoAmedisys to Buy Intercity Home Care, Boosts Personal Care Arm - Nasdaq - September 2 at 1:09 AM logoHaemonetics Grows on Strong Plasma, Blood Center Sluggish - Nasdaq - September 2 at 1:09 AM logoVWR Awaits Merger Closure, Stock Upside Potential Limited - Nasdaq - August 31 at 7:46 PM logoCooper (COO) Poised to Grow on Specialty Lenses Prospects ... - Nasdaq - August 31 at 7:46 PM logoInsider Selling: IDEXX Laboratories, Inc. (IDXX) Chairman Sells 13,000 Shares of Stock - August 30 at 7:16 PM logoLabCorp & Interpace Extend Deal, Boost Cancer Portfolio - Nasdaq - August 30 at 12:47 AM logoLabCorp Grows on Solid Diagnostics, Currency Woes a Drag - Nasdaq - August 30 at 12:47 AM logoIDEXX Laboratories (IDXX), Great Growth Pick: Here's Why - Yahoo Finance - August 27 at 6:39 PM logoIDEXX Laboratories (IDXX), Great Growth Pick: Here's Why - August 26 at 6:06 AM logoIDEXX Laboratories, Inc. (IDXX) Director Sells $394,073.08 in Stock - August 25 at 8:08 PM logoIDEXX Laboratories, Inc. (IDXX) Director Rebecca M. Henderson Sells 5,156 Shares - August 25 at 7:44 PM logoWhy IDEXX Laboratories (IDXX) Isn't Done Growing Earnings Yet - August 25 at 6:59 AM logoWhy IDEXX Laboratories (IDXX) Isn't Done Growing Earnings Yet - August 25 at 6:59 AM logoWhy IDEXX Laboratories (IDXX) Isn't Done Growing Earnings Yet - August 25 at 6:59 AM logoIDEXX Labs Is 'Top Dog' - August 25 at 6:59 AM logoIDEXX Laboratories, Inc. (IDXX) Upgraded to "Buy" by Bank of America Corporation - August 23 at 9:16 AM logoQuality Systems Professional Service a Drag, Competition Rife - Nasdaq - August 23 at 1:13 AM logoCanaccord Genuity Reiterates Buy Rating for IDEXX Laboratories, Inc. (IDXX) - August 22 at 9:26 PM logoHere's Why You Must Add Chemed (CHE) Stock to Your Portfolio - Nasdaq - August 21 at 6:59 PM logoIDEXX Laboratories' (IDXX) "Buy" Rating Reiterated at Stifel Nicolaus - August 21 at 12:02 PM logoQ3 2017 Earnings Estimate for IDEXX Laboratories, Inc. Issued By William Blair (IDXX) - August 21 at 2:54 AM logoIDEXX Laboratories, Inc. (IDXX) Receives Consensus Rating of "Hold" from Analysts - August 19 at 3:16 PM logoGlobus Medical's Robotic Guidance System Gets FDA Approval - Nasdaq - August 19 at 12:39 AM logoIdexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $9 million of ... - Nasdaq - August 19 at 12:39 AM logoHere's Why You Should Invest in IDEXX Laboratories (IDXX) Now - August 18 at 5:17 AM logoIdexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $9 million of ... - August 18 at 5:17 AM logoInsider Selling: IDEXX Laboratories, Inc. (IDXX) CEO Sells 18,000 Shares of Stock - August 16 at 10:26 PM logoInsider Selling: IDEXX Laboratories, Inc. (IDXX) CEO Sells 20,000 Shares of Stock - August 16 at 10:26 PM



IDEXX Laboratories (IDXX) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff